This therapy reduces bladder cancer deaths by 25%

A groundbreaking protocol promises significant advances for patients with bladder cancer. New therapeutic combinations show encouraging results in terms of survival.

Researchers have tested a combination of chemotherapy and immunotherapy. The goal: to reduce recurrences and improve patients' quality of life.


In France, each year, between 13,000 and 20,000 new cases of bladder cancer are diagnosed. Among these, about a quarter involve more aggressive forms, where tumors invade the bladder muscle. These "invasive" forms pose significant therapeutic challenges, as they are more difficult to treat and are often associated with an increased risk of complications and recurrences.

The standard treatment for patients with bladder cancer generally involves chemotherapy, followed by a major surgical procedure known as a radical cystectomy, which involves removing the bladder entirely. However, despite this protocol being considered the gold standard, the risk of disease recurrence remains a concern, with a significant number of patients relapsing after surgery.

In this context, immunotherapy, as a complement to existing treatments, could offer an effective alternative for these patients to reduce recurrences.

Durvalumab, a monoclonal antibody used in combination with chemotherapy, has shown promising results in the NIAGARA trial. This treatment has led to a significant reduction in recurrences and mortality rates. Researchers observed an overall survival rate of 82.2% at 24 months for patients receiving durvalumab, compared to 75.2% in the control group. The risk of recurrence decreased by 32%, and overall survival increased by 25%.

Immunotherapy works by neutralizing the protective mechanisms set up by cancer cells to evade immune system attacks. By disabling these defenses, it allows immune cells to better recognize and destroy tumor cells. This approach not only promotes a more effective immune response but also prolongs patient survival by delaying disease progression.

In addition to these positive results, no additional toxicity was noted with the addition of durvalumab. This advancement could redefine therapeutic standards in the coming years.